Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
about
Striving for optimal bronchodilation: focus on olodaterolDifferential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterolPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDPositioning new pharmacotherapies for COPDThe Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseaseA review of nebulized drug delivery in COPDOnce-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by ageComparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol.Olodaterol: a review of its use in chronic obstructive pulmonary disease.Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.Tiotropium/Olodaterol: A Review in COPD.Recent advances in the management of chronic obstructive pulmonary disease.Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.Systematic review comparing LABA, olodaterol, and indacaterol: limitations.Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.What Does the TOVITO Programme Tell Us about How We Can Manage COPD?
P2860
Q26752887-E647A8F2-7C3B-4F10-99E7-1D716753226EQ26775244-2EEDC569-2386-44FD-94D3-9499E79815E5Q26778685-722B3B64-CF28-4190-8CFF-89DA753E11A2Q26798659-9226E7A4-FE60-484D-B93D-2B6436FE22F1Q28068078-55BAAA4B-6A26-4987-974A-98267326736BQ28075295-BADF7845-1F93-4521-8DD5-86B8496A895BQ34011640-4F3948EF-92BE-4CC1-88A5-A1295DF4B955Q35766346-5FE8909B-B85E-461D-B86C-12DFEC634C3DQ35778149-44A13A32-8CA9-4D52-A745-8A62B9ED919CQ35875281-2A348E86-8FE6-400A-9419-93BD9DAF50D2Q35965128-7C07B635-AA23-4592-B9E9-C9D797596C44Q35994264-4B54D5B2-371A-4A2B-BEB1-0749E4218884Q36729122-C3B054CD-F109-4AA7-BDB8-F32C558B83C9Q37278903-B0E420C1-8BB4-43AB-BD60-AC5CDBDD55D8Q37283438-84CD5D11-60F7-41DB-A4C0-15079856488CQ37397852-4BC65B40-9DD6-4165-8436-2E189B11A7AAQ37603579-BA7AB908-3903-4B2A-9083-29046035E7A5Q38352425-7C1A727E-2A64-4E27-BF9E-2A41ADDDE9CDQ38379269-AD0C68C8-5A58-40FC-9E5F-ECC89F8816E6Q38639661-E5A35692-E1E1-4D5D-969E-015038830C52Q38673383-D1B82DAA-5479-4AA3-8F2B-CC46B0F97A80Q38701325-480F38FA-6F52-4048-A2B4-846057BD7D18Q38982942-9970A49C-76CD-4E72-87D4-146C5505454FQ39037235-D9755291-94C2-4992-907A-7E127A1C821CQ39627403-B59955D2-9FE7-4E69-97A6-174E8A014CC9Q39674585-4F30C237-2B79-4BE7-926B-70629E9D29C3Q42634011-BF5ADF3F-D9FA-4C78-9AC3-95D024BE6353Q47159721-B3EB7EFD-E73F-4300-B8E9-62959A14B6DCQ47375559-52065510-BB94-453B-92BD-11F279F8CD20Q47657304-936DAC41-C911-4004-942A-F01877022FA1Q47915131-E07BDDCE-8EA6-4950-BA00-87213842F4F7Q47966525-0C919818-7EFE-4DC8-8A20-7C84404698EAQ55133367-3D590B5D-69AB-4BFA-9878-E492988351A3Q59131559-7E9BB82F-9320-4DAC-8753-86194D726156
P2860
Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of olodate ...... two replicate 48-week studies.
@ast
Efficacy and safety of olodate ...... two replicate 48-week studies.
@en
type
label
Efficacy and safety of olodate ...... two replicate 48-week studies.
@ast
Efficacy and safety of olodate ...... two replicate 48-week studies.
@en
prefLabel
Efficacy and safety of olodate ...... two replicate 48-week studies.
@ast
Efficacy and safety of olodate ...... two replicate 48-week studies.
@en
P2093
P2860
P356
P1476
Efficacy and safety of olodate ...... two replicate 48-week studies.
@en
P2093
Alan Hamilton
Gary T Ferguson
Gregory J Feldman
Lawrence Korducki
Lisa Allen
Paul Sachs
Peter Hofbauer
P2860
P304
P356
10.2147/COPD.S61717
P407
P577
2014-06-16T00:00:00Z